Hantz Financial Services Inc. Acquires 84,953 Shares of Boston Scientific Corporation $BSX

Hantz Financial Services Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 211.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 125,040 shares of the medical equipment provider’s stock after buying an additional 84,953 shares during the quarter. Hantz Financial Services Inc.’s holdings in Boston Scientific were worth $12,208,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Steph & Co. bought a new position in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific during the third quarter valued at approximately $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter valued at approximately $26,000. United Community Bank raised its position in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the period. Finally, Kilter Group LLC acquired a new stake in shares of Boston Scientific in the second quarter worth $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 191,105 shares of company stock worth $18,067,697 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on BSX shares. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Monday. The Goldman Sachs Group reiterated a “buy” rating and issued a $112.00 price objective on shares of Boston Scientific in a research note on Friday, January 9th. Canaccord Genuity Group cut their price objective on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. Finally, Citigroup reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $123.26.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $91.56 on Wednesday. The firm has a market capitalization of $135.73 billion, a PE ratio of 48.96, a PEG ratio of 1.63 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The business’s 50 day moving average is $94.89 and its 200-day moving average is $99.29.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.